Skip to main content

Table 1 Patient Demographics

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Characteristic

Cohort 1

Cohort 2

Vemurafenib 6 weeks (N = 38)

Vemurafenib 7–18 weeks (N = 15)

Age (yr)

 Mean (SD)

48.6 (12.79)

48.5 (13.90)

 Median

50.5

48.0

 Range

21–73

26–67

Gender – no. (%)

 Male

15 (39.5)

6 (40.0)

 Female

23 (60.5)

9 (60.0)

Race – no. (%)

 White

35 (92.1)

15 (100.0)

 Decline

2 (5.3)

0 (0.0)

 Other

1 (2.6)

0 (0.0)

Metastasis stage – no. (%)

 M1a

9 (23.7)

2 (13.3)

 M1b

13 (34.2)

3 (20.0)

 M1c

16 (42.1)

10 (66.7)

LDH level – no. (%)

  ≤ ULN

17 (44.7)

5 (33.3)

  > ULN

17 (44.7)

8 (53.3)

 Not measured

4 (10.5)

2 (13.3)

Prior therapy – no. (%)

 Surgery

34 (89.5)

13 (86.7)

 Radiation

7 (18.4)

8 (53.3)

 Chemotherapy

4 (10.5)

1 (6.7)

 Anti-PD1/PDL1

0

0

Mutation – no. (%)

 BRAF

38 (100.0)

15 (100.0)

 cKIT

1 (2.6)

0 (0.0)

 Other

1 (2.6)

0 (0.0)

Performance Status

 0

24 (63.2)

8 (53.3)

 1

14 (36.8)

7 (46.7)

  1. Race of ‘Other’ had the description ‘Not specified’ recorded